Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016750 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
A Phase 3 study of Dystrophic Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa, sponsored by Krystal Biotech.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT07016750 is a Phase 3 study of Dystrophic Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 16 participants, below the 18-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (11% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07016750, a Phase 3 study of Dystrophic Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa, is actively recruiting participants, sponsored by Krystal Biotech.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Conditions Studied
Interventions
- BIOLOGICAL KB803
- DRUG Placebo
Study Locations (5)
California
- Mission Dermatology Center - Rancho Santa Margarita
Florida
- Skin Research Institute - Coral Gables
Massachusetts
- UMass Memorial Medical Center - Worcester
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- Texas Dermatology and Laser Specialists - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016750
The ClinicalTrials.gov registry entry for NCT07016750 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 18-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (11% lower). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 2 interventions - of which KB803 is the first listed.
NCT07016750 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07016750 about?
NCT07016750 is a clinical study titled "A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa". KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
What is the current status of trial NCT07016750?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2025-06-20. Estimated completion is 2026-12.
What conditions does trial NCT07016750 study?
This clinical trial studies the following conditions: Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa.
What interventions are being tested in trial NCT07016750?
The interventions under investigation include: KB803 (BIOLOGICAL), Placebo (DRUG).
Who is sponsoring clinical trial NCT07016750?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016750 being conducted?
This trial has 5 study locations across California, Florida, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dystrophic Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
ACTIVE NOT RECRUITING · Phase 3
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
Long-Term Follow-up Protocol
RECRUITING
-
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 2
-
MSC EVs in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
COMPLETED · Phase 1
Explore more on PlainTrial
Dystrophic Epidermolysis Bullosa
All registered trials for this condition
Recessive Dystrophic Epidermolysis Bullosa
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.